Add 2 More Reports For 20% off

Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Doxorubicin Market Outlook

The global doxorubicin market size attained a value of USD 1,295.95 million in 2023 driven highly by the rising incidences of cancer across the globe. The market is anticipated to grow at a CAGR of 6.4% during the forecast period of 2024-2032 to attain a value of USD 2,264.98 million by 2032.

Global Doxorubicin Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Breast Cancer Segment to Hold a Significant Market Share of the Market Over the Forecast Period

Doxorubicin finds its largest regional market in North America. The region is expected to retain its dominance over the global market in the coming years owing to the increase in cancer incidence and associated mortality rate. The United States registered the highest cancer rate and considerable deaths in 2020. Meanwhile, the regional market in the Asia Pacific is estimated to grow with healthy CAGR over the period owing to the highest mortality rate in China. In terms of application, the most prevalent cancers include breast cancer, prostate cancer, lung cancer, colon and rectum cancer, and skin melanoma. Hence, the segment of breast cancer is projected to account for the maximum use of the drug in the coming years. According to WHO, the number of breast cancer cases found in the year 2020 was around 2.26 million, which is about 11.7% of all the new cases registered that year.

Doxorubicin: Market Segmentation

Doxorubicin (C27H29NO11) is a medication for chemotherapy used in the treatment of various cancer diseases, including breast cancer, bladder cancer, lymphoma, and others. It is administered as an intravenous drug along with other chemotherapy agents and is sold under different brand names including Adriamycin, and Caelyx, among others.

Global Doxorubicin Market by Segment

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The applications for doxorubicin include:

  • Ovarian Cancer
  • Multiple Myeloma
  • Kaposi Sarcoma
  • Leukaemia
  • Bone Sarcoma
  • Breast Cancer
  • Endometrial Cancer
  • Gastric Cancer
  • Liver Cancer
  • Kidney Cancer
  • Other Cancer

The EMR report looks into the regional markets of doxorubicin like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Global Doxorubicin Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Rising Cancer Cases and Related Deaths to Bolster the Demand for Doxorubicin

The primary driver for the market growth of doxorubicin is the rising incidences of cancer across the globe. This increase can be attributed to the presence of carcinogens in day-to-day use products in the current lifestyle of people. According to the latest statistics provided by the Union for International Cancer Control (UICC), the number of cancer cases has risen to 19.3 million and 10 million cancer related deaths in 2020. This rise is expected to continue in the forthcoming years, providing lucrative opportunities for demand growth of doxorubicin. Additionally, supportive actions from the government for technological progress in clinical diagnostics and therapeutics such as intravenous free therapy and digital microfluidics for biochemical analysis is expected to boost the market growth of the drug over the forecast period. However, it is noteworthy that certain side effects, such as hand-foot syndrome, typhlitis, heart failure, among others, can potentially impede the growing demand.

Key Industry Players in the Global Doxorubicin Market

The report presents a detailed analysis of the following key players in the global doxorubicin market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Cipla, Inc.
  • Cadila Pharmaceuticals Ltd.
  • Others

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Application
  • Distribution Channel
  • Region
Breakup by Application
  • Ovarian Cancer
  • Multiple Myeloma
  • Kaposi Sarcoma
  • Leukaemia
  • Bone Sarcoma
  • Breast Cancer
  • Endometrial Cancer
  • Gastric Cancer
  • Liver Cancer
  • Kidney Cancer
  • Other Cancers
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Cipla, Inc.
  • Cadila Pharmaceuticals Ltd.
  • SRS PHARMACEUTICALS PVT. LTD.
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

Globally, doxorubicin market reached a value of USD 1,295.95 million in 2023.

The market is projected to expand at a CAGR of 6.4% from 2024 to 2032, growing to USD 2,264.98 million by 2032.

The market is being driven by the rising cases of cancer and the associated mortality rates, along with an increase in the number of breast cancer patients worldwide.

The industry is primarily being driven the supportive actions from the government for technological progress in clinical diagnostics and therapeutics.

The major regional markets for doxorubicin are North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.

Doxorubicin finds its applications in the treatment of ovarian cancer, multiple myeloma, kaposi sarcoma, leukaemia, bone sarcoma, breast cancer, endometrial cancer, gastric cancer, liver cancer, and kidney cancer, among other types of cancers.

The major players in the industry are Pfizer Inc., Sun Pharmaceutical Industries Limited, Cipla, Inc., and Cadila Pharmaceuticals Ltd., among others.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63 287899028, +63 967 048 3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124